File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/1479-5876-12-52
- Scopus: eid_2-s2.0-84895430477
- PMID: 24559316
- WOS: WOS:000335533000002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
Title | Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia |
---|---|
Authors | |
Keywords | Chronic lymphocytic leukemia DNA methylation MicroRNA TP53 network Tumor suppressor |
Issue Date | 2014 |
Publisher | BioMed Central Ltd. The Journal's web site is located at http://www.translational-medicine.com/home/ |
Citation | Journal of Translational Medicine, 2014, v. 12, article no. 52 How to Cite? |
Abstract | BACKGROUND: TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation might correlate with miR-203 or miR-124-1 methylation in CLL. METHODS: miR-34b/c, miR-34a and DAPK1 methylation was studied in 11 normal controls, 7 CLL cell lines, and 78 diagnostic CLL samples by methylation-specific polymerase chain reaction. MEC-1 cells were treated with 5-Aza-2'-deoxycytidine for reversal of methylation-associated miRNA silencing. Tumor suppressor properties of miR-34b were demonstrated by over-expression of precursor miR-34b in MEC-1 cells. RESULTS: miR-34b/c promoter was unmethylated in normal controls, but completely methylated in 4 CLL cell lines. miR-34b/c expression was inversely correlated with miR-34b/c methylation. Different MSP statuses of miR-34b/c, including complete methylation and complete unmethylation, were verified by quantitative bisulfite pyrosequencing. 5-Aza-2'-deoxycytidine treatment resulted in promoter demethylation and miR-34b re-expression in MEC1 cells. Moreover, over-expression of miR-34b resulted in inhibition of cellular proliferation and increased cell death. In primary CLL samples, miR-34a, miR-34b/c and DAPK1 methylation was detected in 2.6%, 17.9% and 34.6% of patients at diagnosis respectively. Furthermore, 39.7%, 3.8% and 2.6% patients had methylation of one, two or all three genes respectively. Overall, 46.2% patients had methylation of at least one of these three genes. Besides, miR-34b/c methylation was associated with methylation of miR-34a (P = 0.03) and miR-203 (P = 0.012) in CLL. CONCLUSIONS: Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study. |
Persistent Identifier | http://hdl.handle.net/10722/200462 |
ISSN | 2023 Impact Factor: 6.1 2023 SCImago Journal Rankings: 1.611 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, LQ | en_US |
dc.contributor.author | Kwong, YL | en_US |
dc.contributor.author | Wong, KF | en_US |
dc.contributor.author | Kho, CSB | en_US |
dc.contributor.author | Jin, D | en_US |
dc.contributor.author | Tse, EWC | en_US |
dc.contributor.author | Rosen, A | en_US |
dc.contributor.author | Chim, JCS | en_US |
dc.date.accessioned | 2014-08-21T06:47:27Z | - |
dc.date.available | 2014-08-21T06:47:27Z | - |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Journal of Translational Medicine, 2014, v. 12, article no. 52 | en_US |
dc.identifier.issn | 1479-5876 | - |
dc.identifier.uri | http://hdl.handle.net/10722/200462 | - |
dc.description.abstract | BACKGROUND: TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation might correlate with miR-203 or miR-124-1 methylation in CLL. METHODS: miR-34b/c, miR-34a and DAPK1 methylation was studied in 11 normal controls, 7 CLL cell lines, and 78 diagnostic CLL samples by methylation-specific polymerase chain reaction. MEC-1 cells were treated with 5-Aza-2'-deoxycytidine for reversal of methylation-associated miRNA silencing. Tumor suppressor properties of miR-34b were demonstrated by over-expression of precursor miR-34b in MEC-1 cells. RESULTS: miR-34b/c promoter was unmethylated in normal controls, but completely methylated in 4 CLL cell lines. miR-34b/c expression was inversely correlated with miR-34b/c methylation. Different MSP statuses of miR-34b/c, including complete methylation and complete unmethylation, were verified by quantitative bisulfite pyrosequencing. 5-Aza-2'-deoxycytidine treatment resulted in promoter demethylation and miR-34b re-expression in MEC1 cells. Moreover, over-expression of miR-34b resulted in inhibition of cellular proliferation and increased cell death. In primary CLL samples, miR-34a, miR-34b/c and DAPK1 methylation was detected in 2.6%, 17.9% and 34.6% of patients at diagnosis respectively. Furthermore, 39.7%, 3.8% and 2.6% patients had methylation of one, two or all three genes respectively. Overall, 46.2% patients had methylation of at least one of these three genes. Besides, miR-34b/c methylation was associated with methylation of miR-34a (P = 0.03) and miR-203 (P = 0.012) in CLL. CONCLUSIONS: Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study. | - |
dc.language | eng | en_US |
dc.publisher | BioMed Central Ltd. The Journal's web site is located at http://www.translational-medicine.com/home/ | - |
dc.relation.ispartof | Journal of Translational Medicine | en_US |
dc.rights | Journal of Translational Medicine. Copyright © BioMed Central Ltd. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Chronic lymphocytic leukemia | - |
dc.subject | DNA methylation | - |
dc.subject | MicroRNA | - |
dc.subject | TP53 network | - |
dc.subject | Tumor suppressor | - |
dc.subject.mesh | Bone Marrow Cells - drug effects - metabolism | - |
dc.subject.mesh | Death-Associated Protein Kinases - genetics - metabolism | - |
dc.subject.mesh | Epigenesis, Genetic - drug effects | - |
dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis - genetics | - |
dc.subject.mesh | MicroRNAs - genetics - metabolism | - |
dc.title | Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia | en_US |
dc.type | Article | en_US |
dc.identifier.email | Kwong, YL: ylkwong@hku.hk | en_US |
dc.identifier.email | Jin, D: dyjin@hku.hk | en_US |
dc.identifier.email | Tse, EWC: ewctse@hku.hk | en_US |
dc.identifier.email | Chim, JCS: jcschim@hku.hk | en_US |
dc.identifier.authority | Kwong, YL=rp00358 | en_US |
dc.identifier.authority | Jin, D=rp00452 | en_US |
dc.identifier.authority | Tse, EWC=rp00471 | en_US |
dc.identifier.authority | Chim, JCS=rp00408 | en_US |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1186/1479-5876-12-52 | - |
dc.identifier.pmid | 24559316 | - |
dc.identifier.pmcid | PMC3941938 | - |
dc.identifier.scopus | eid_2-s2.0-84895430477 | - |
dc.identifier.hkuros | 234371 | en_US |
dc.identifier.hkuros | 231433 | - |
dc.identifier.volume | 12 | en_US |
dc.identifier.isi | WOS:000335533000002 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1479-5876 | - |